Disc Medicine, Inc. - Common Stock, par value $0.0001 per share (IRON)

CUSIP: 254604101

Q1 2024 13F Holders as of 31 Mar 2024

Holder snapshot 7 signals
Share change
+1,962,129
Put/Call ratio
397%
SEC-reported price per share
$62.26
Number of holders
125
Value change
+$124,372,681
Number of buys
84
Open additional details 1 more signal available
Number of sells
40
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
44,597,121

Security key

254604101

Report period

Q1 2024

Institutions

125

Top holders

10

Ownership snapshot

Top reported holders of IRON - Disc Medicine, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Braden M. Leonard
Disclosed value leader
Braden M. Leonard
Comparable rows
0/15
Latest evidence
23 Jan 2024
3/4/5 13F Highest disclosed value: $354,993,375 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Braden M. Leonard has the largest disclosed position value at $354.99M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Braden M. Leonard's linked filing trail.
Disclosed position value Top 5
Braden M. Leonard $354.99M
Atlas Venture Fund X, L.P. $108.27M
Novo Holdings A/S $73.79M
James B. Tananbaum $27.84M
Atlas Venture Opportunity Fund II... $14.77M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Braden M. Leonard
3/4/5
10%+ Owner
—
denominator unverified
$354,993,375
5,247,500 shares
— 26 Oct 2022
Atlas Venture Fund X, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$108,274,637
1,600,512 shares
— 23 Jan 2024
Novo Holdings A/S
3/4/5
10%+ Owner
—
denominator unverified
$73,790,726
1,090,772 shares
— 28 Jun 2023
James B. Tananbaum
3/4/5
Director, 10%+ Owner
—
mixed-class rows
$27,837,975
428,745 shares
mixed-class rows
— 04 Oct 2021
Atlas Venture Opportunity Fund II, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$14,769,754
218,326 shares
— 29 Dec 2022
Carl L. Gordon
3/4/5
Director, 10%+ Owner
—
denominator unverified
—
17,245 shares
— 04 Oct 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
125
Shares
22,155,328
Rows available
125
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders
125
Q1 2024 holders
125
Holder diff
0
Investor Q1 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q1 2024 value Q1 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .